1 - 8 of 8 Results Clear All
With $4.8 million from the NIH, Gladstone scientists will investigate how the protein apoE4 causes neurodegeneration in Alzheimer’s disease.
Grants News Release Neurological Disease Krogan Lab Mahley Lab
Gladstone began as a single entity with a single purpose. But as the scientists followed the science—unencumbered by the red tape of bureaucracy—the purpose, and the focus, grew.
History Institutional News Cardiovascular Disease Data Science and Biotechnology Neurological Disease Virology and Immunology Finkbeiner Lab Greene Lab Mahley Lab Mucke Lab
As clinical trials in Alzheimer's disease have failed, Gladstone investigators are taking innovative approaches to understanding the disease and finding new therapeutic targets.
Research Dementia Neurological Disease Huang Lab Mahley Lab Mucke Lab Palop Lab Aging Disease ModelsLearn more about Gladstone's founding President in this video celebrating our 40th anniversary.
History Institutional News Mahley Lab
A look at the distinct eras defined by Gladstone’s three presidents
History Institutional News Mahley Lab Srivastava Lab
E-Scape Bio, a Gladstone spin-off company, extends its Series A financing to generate novel therapies to treat neurodegenerative disorders
Huang Lab Mahley Lab
SAN FRANCISCO, CA—Alzheimer’s disease is one of the greatest challenges facing modern medicine, but there is new hope in the fight against this deadly disease.
Huang Lab Mahley Lab Neurological Disease
SAN FRANCISCO, CA—Scientists at the Gladstone Institutes are recommending a shift in efforts to treat Alzheimer’s disease by developing drugs that target the apoE4 protein, which has long been associated with an increased risk for the disease.
Huang Lab Mahley Lab